ストックスクリーナーアプリを入手
22.84
3.91%
0.86
アフターアワーズ：
22.84
Uniqure N V (QURE) 最新ニュース
QURE Investigation Reminder: Kessler Topaz Meltzer & - GlobeNewswire
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences - MSN
Setup Watch: Is AMPGW subject to activist investor interestEarnings Risk Report & Growth Focused Stock Pick Reports - baoquankhu1.vn
Downgrade Watch: Will uniQure NV stock benefit from M ALong Setup & Daily Market Momentum Tracking - baoquankhu1.vn
Robert Gut Sells 25,613 Shares of uniQure (NASDAQ:QURE) Stock - MarketBeat
RSI Check: Can uniQure NV continue delivering strong returnsJuly 2025 Snapshot & AI Powered Market Entry Ideas - baoquankhu1.vn
Health Check: How Prudently Does UniQure (NASDAQ:QURE) Use Debt? - 富途牛牛
uniQure stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Nigeria
Cantor Fitzgerald Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $55 - 富途牛牛
uniQure stock rating reiterated at Overweight by Cantor Fitzgerald By Investing.com - Investing.com Australia
uniQure stock falls after FDA feedback on gene therapy application - MSN
Ideas Watch: Does uniQure NV stock trade at a discount to peersJuly 2025 Outlook & Daily Chart Pattern Signal Reports - moha.gov.vn
How Investors Are Reacting To uniQure (QURE) After Its Pivotal FDA Type A Meeting On AMT-130 - Yahoo Finance
Assessing uniQure (QURE) Valuation After Recent Volatility And Gene Therapy Progress - Yahoo Finance
uniQure updates gene therapy pipeline and regulatory outlook - TipRanks
uniQure N.V. Updates on Gene Therapy Developments - TradingView — Track All Markets
uniQure (NASDAQ:QURE) Director Sells $174,319.20 in Stock - MarketBeat
uniQure (NASDAQ:QURE) Shares Down 9.2%Should You Sell? - MarketBeat
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, - GlobeNewswire
Is UniQure (QURE) One of the Promising Stocks to Buy Under $50? - Insider Monkey
uniQure Shares Skyrocket After Positive Huntington’s Disease Gene Therapy Data - MSN
uniQure (NASDAQ:QURE) Rating Lowered to Sell at Wall Street Zen - MarketBeat
uniQure N.V. Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure N.V. Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure (NASDAQ:QURE) Shares Gap UpHere's What Happened - MarketBeat
uniQure schedules FDA meeting to discuss accelerated approval for HD therapy - Investing.com Nigeria
uniQure (QURE) Surges on FDA Meeting for Gene Therapy Approval - GuruFocus
UniQure Announces FDA Type A Meeting To Discuss BLA Data For Huntington's Gene Therapy - Nasdaq
uniQure stock soars after FDA meeting scheduled on Huntington’s therapy - Investing.com
US-listed shares of uniQure rise 13% premarket as FDA review talks revive hopes for Huntington's therapy - marketscreener.com
uniQure's (QURE) Gene Therapy for Huntington's Disease Advances with FDA Meeting - GuruFocus
uniQure gains as FDA sets up meeting on gene therapy (QURE:NASDAQ) - Seeking Alpha
uniQure stock soars after FDA meeting scheduled on Huntington’s therapy By Investing.com - Investing.com South Africa
uniQure prepares for FDA Type A meeting on AMT-130 - TipRanks
uniQure schedules FDA meeting to discuss accelerated approval for HD therapy By Investing.com - Investing.com South Africa
uniQure Announces Type A Meeting Scheduled with FDA - The Manila Times
uniQure N.V. Schedules FDA Meeting for AMT-130 Approval - TradingView — Track All Markets
FDA to review data on experimental Huntington's gene therapy at uniQure - Stock Titan
UniQure N.V. (QURE) Stock Analysis: A Biotech Powerhouse With 137% Potential Upside - DirectorsTalk Interviews
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourage - GuruFocus
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Prime Publishers, Inc.
Is uniQure N.V. stock supported by strong fundamentals2025 Risk Factors & Verified Momentum Stock Alerts - ulpravda.ru
uniQure: Now What? (NASDAQ:QURE) - Seeking Alpha
How sustainable is uniQure N.V. stock dividend payout2025 Growth vs Value & Weekly Market Pulse Alerts - ulpravda.ru
Pullback Watch: Is uniQure N.V. stock attractive for long term wealth building2025 Market Outlook & Weekly Hot Stock Watchlists - ulpravda.ru
QURE Investigation: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
How (QURE) Movements Inform Risk Allocation Models - Stock Traders Daily
QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP - Business Wire
Wells Fargo Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $60 - 富途牛牛
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - FinancialContent
uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen - MarketBeat
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure N.V. (QURE) Stock Analysis: Unveiling a 131% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
How reliable is uniQure NV UQ1 stock dividend growth2025 Big Picture & Technical Pattern Based Buy Signals - moha.gov.vn
4.73%
0.92%
大文字化:
|
ボリューム (24 時間):